BeiGene, Ltd. Form 4 March 20, 2017

# FORM 4

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

**SECURITIES** 

OMB Number:

3235-0287

Expires:

January 31, 2005

0.5

Estimated average burden hours per

**OMB APPROVAL** 

response...

if no longer subject to Section 16. Form 4 or Form 5 obligations

may continue.

See Instruction

Check this box

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person \* **OYLER JOHN** 

2. Issuer Name and Ticker or Trading Symbol

5. Relationship of Reporting Person(s) to

Issuer

(Last)

(City)

(First) (Middle) BeiGene, Ltd. [BGNE]

(Check all applicable)

C/O MOURANT OZANNES **CORPORATE SERVICES. 94** 

SOLARIS AVENUE, CAMANA BAY

3. Date of Earliest Transaction (Month/Day/Year)

03/16/2017

\_X\_\_ Director X\_\_ 10% Owner \_ Other (specify X\_ Officer (give title below)

Chief Executive Officer

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check

Applicable Line)

\_X\_ Form filed by One Reporting Person Form filed by More than One Reporting

#### GRAND CAYMAN, E9 KY1-1108

| (City)                               | (State) (2                           | Zip) Table  | e I - Non-D                             | erivative S  | Securi                | ties Acquire         | ed, Disposed of, o   | r Beneficially                                | y Owned   |
|--------------------------------------|--------------------------------------|---|---|--|-----------------------|----------------------|--|---|---|
| 1.Title of<br>Security<br>(Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed<br>Execution Date, if<br>any<br>(Month/Day/Year) | 3.<br>Transaction<br>Code<br>(Instr. 8) | 4. Securities Accord Disposed of (Instr. 3, 4 and 5) |                       | (D)                  | 5. Amount of<br>Securities<br>Beneficially<br>Owned<br>Following<br>Reported | 6. Ownership Form: Direct (D) or Indirect (I) | 7. Nature<br>Indirect<br>Beneficia<br>Ownersh<br>(Instr. 4) |
| American<br>Depositary<br>Shares (1) | 03/16/2017                           |   | Code V S(2)                             | Amount 15,838  | (A)<br>or<br>(D)<br>D | Price \$ 38.7581 (3) | Transaction(s) (Instr. 3 and 4) 197,640                                      | (Instr. 4)                                    |   |
| American<br>Depositary<br>Shares (1) | 03/16/2017                           |   | S(2)                                    | 200  | D                     | \$ 39.37             | 197,440  | D   |   |
| American<br>Depositary<br>Shares (1) | 03/17/2017                           |   | S(2)                                    | 2,717  | D                     | \$<br>40.0209<br>(4) | 194,723  | D   |   |

7. Nature of Indirect Beneficial Ownership (Instr. 4)

### Edgar Filing: BeiGene, Ltd. - Form 4

| American<br>Depositary<br>Shares (1) | 03/20/2017 | S(2) | 13,234 | D | \$ 40.019<br>(5) | 181,489    | D |                  |
|--------------------------------------|------------|------|--------|---|------------------|------------|---|------------------|
| Ordinary<br>Shares                   |            |      |        |   |                  | 23,436,468 | D |                  |
| Ordinary<br>Shares                   |            |      |        |   |                  | 29,890,174 | I | See footnote (6) |
| Ordinary<br>Shares                   |            |      |        |   |                  | 10,000,000 | I | See footnote (7) |
| Ordinary<br>Shares                   |            |      |        |   |                  | 102,188    | I | See footnote (8) |
| Ordinary<br>Shares                   |            |      |        |   |                  | 8,000,000  | I | See footnote (9) |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

9. Nu Deriv Secur Bene Own Follo Repo Trans (Instr

# Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of | 2.          | 3. Transaction Date | 3A. Deemed         | 4.          | 5.         | 6. Date Exerc | isable and | 7. Titl | le and       | 8. Price of | 9 |
|-------------|-------------|---------------------|--------------------|-------------|------------|---------------|------------|---------|--------------|-------------|---|
| Derivative  | Conversion  | (Month/Day/Year)    | Execution Date, if | Transaction | orNumber   | Expiration Da | ate        | Amou    | ınt of       | Derivative  | J |
| Security    | or Exercise |                     | any                | Code        | of         | (Month/Day/   | Year)      | Under   | rlying       | Security    | 5 |
| (Instr. 3)  | Price of    |                     | (Month/Day/Year)   | (Instr. 8)  | Derivative | e             |            | Secur   | ities        | (Instr. 5)  | ] |
|             | Derivative  |                     |                    |             | Securities |               |            | (Instr. | 3 and 4)     |             | ( |
|             | Security    |                     |                    |             | Acquired   |               |            |         |              |             | } |
|             |             |                     |                    |             | (A) or     |               |            |         |              |             | J |
|             |             |                     |                    |             | Disposed   |               |            |         |              |             | - |
|             |             |                     |                    |             | of (D)     |               |            |         |              |             | ( |
|             |             |                     |                    |             | (Instr. 3, |               |            |         |              |             |   |
|             |             |                     |                    |             | 4, and 5)  |               |            |         |              |             |   |
|             |             |                     |                    |             |            |               |            |         | Amount       |             |   |
|             |             |                     |                    |             |            |               |            |         |              |             |   |
|             |             |                     |                    |             |            | Date          | Expiration | Title   | or<br>Number |             |   |
|             |             |                     |                    |             |            | Exercisable   | Date       | Title   | of           |             |   |
|             |             |                     |                    | C + V       | (A) (D)    |               |            |         |              |             |   |
|             |             |                     |                    | Code V      | (A) (D)    |               |            |         | Shares       |             |   |

# **Reporting Owners**

| Reporting Owner Name / Address | Relationships |           |         |       |  |  |
|--------------------------------|---------------|-----------|---------|-------|--|--|
|                                | Director      | 10% Owner | Officer | Other |  |  |

Reporting Owners 2

Edgar Filing: BeiGene, Ltd. - Form 4

OYLER JOHN C/O MOURANT OZANNES CORPORATE SERVICES 94 SOLARIS AVENUE, CAMANA BAY GRAND CAYMAN, E9 KY1-1108

X Chief Executive Officer

### **Signatures**

/s/ Howard Liang, as Attorney-in-Fact

03/20/2017

\*\*Signature of Reporting Person

Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Each American Depositary Share represents 13 Ordinary Shares
- (2) The sale was effected pursuant to a Rule 105b-1 trading plan adopted by the Reporting Person.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$38.26 to \$39.22, inclusive. The Reporting Person has provided the Issuer, and undertakes to provide to the staff of the Securities and Exchange Commission or any security holder of the Issuer, upon request, full information regarding the number of American Depositary Shares sold at each separate price within the ranges set forth in footnotes (3) to (5).
- (4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$40.00 to \$40.10, inclusive.
- (5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$40.00 to \$40.16, inclusive.
- These securities are held by Oyler Investment LLC, of which 99% of the the limited liability company interest owned by a grantor retain annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.
- (7) These securities are held for the benefit of the Reporting Person in a Roth IRA PENSCO trust account.
- These securities are held by The John Oyler Legacy Trust, of which the Reporting Person's father is a trustee, for the benefit of the Reporting Person's minor child, for which the Reporting Person disclaims beneficial ownership.
- (9) These securities are held in a grantor retained annuity trust, of which the Reporting Person's father is a trustee, for which the Reporting Person disclaims beneficial ownership.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3